Use of non-steroidal anti-inflammatory drugs in pregnancy and oligohydramnios: a review

References

• Laurence L, Brunton J, John S, et al., editors. Non-steroidal anti-inflammatory drugs. In: Goodman and Gill’s The pharmacologic basis of therapeutics. 11th ed. USA: McGraw Hill; 2006. p. 673–706.
   Google Scholar
• Rang HP, Dale MM, Ritter JM, et al. Pharmacology. In: Laurence H, editor. Anti-inflammatory and immunosuppressant drugs. 5th ed. vol. 47. Edinburgh: Churchill Livingston; 2003. p. 244–260.
   Google Scholar
• Jones DA, Carlton DP, McIntyre TM, et al. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem. 1993;268(12):9049–9054. doi: 10.1016/S0021-9258(18)52976-8.
   PubMed Web of Science ®Google Scholar
• Lee E, Maneno MK, Smith L, et al. National patterns of medication use during pregnancy. Pharmacoepidemiol Drug Saf. 2006;15(8):537–545. doi: 10.1002/pds.1241.
   PubMed Web of Science ®Google Scholar
• Antonucci R, Zaffanello M, Puxeddu E, et al. Use of non-steroidal anti-inflammatory drugs in pregnancy: impact on the fetus and newborn. Curr Drug Metab. 2012;13(4):474–490. doi: 10.2174/138920012800166607.
   PubMed Web of Science ®Google Scholar
• Sannerstedt R, Lundborg P, Danielsson BR, et al. Drugs during pregnancy: an issue of risk classification and information to prescribers. Drug Saf. 1996;14(2):69–77. doi: 10.2165/00002018-199614020-00001.
   PubMed Web of Science ®Google Scholar
• Schoenfeld A, Bar Y, Merlob P, et al. NSAIDs: maternal and fetal considerations. Am J Reprod Immunol. 1992;28(3–4):141–147. doi: 10.1111/j.1600-0897.1992.tb00777.x.
   PubMed Web of Science ®Google Scholar
• FDA. FDA recommends avoiding use of NSAIDs in pregnancy at 20 weeks or later because they can result in low amniotic fluid. 2020 FDA Drug Safety Communication. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-avoiding-use-nsaids-pregnancy-20-weeks-or-later-because-they-can-resultlowamniotic#:∼:text=FDA%20is%20warning%20that%20using,fluid%20that%20surrounds%20the%20baby
   Google Scholar
• Scherneck S, Schöpa FL, Entezami M, et al. Reversible oligohydramnios in the second trimester of pregnancy in two patients with long-term diclofenac exposure. Reprod Toxicol. 2015;58:61–64. doi: 10.1016/j.reprotox.2015.08.002.
   PubMed Web of Science ®Google Scholar
• Klauser CK, Briery CM, Martin RW, et al. A comparison of three tocolytics for preterm labor: a randomized clinical trial. J Matern Fetal Neonatal Med. 2014;27(8):801–806. doi: 10.3109/14767058.2013.847416.
   PubMed Web of Science ®Google Scholar
• Ali US, Khubchandani S, Andankar P, et al. Renal tubular dysgenesis associated with in utero exposure to nimesulide. Pediatr Nephrol. 2006;21(2):274–276. doi: 10.1007/s00467-005-2089-0.
   PubMed Web of Science ®Google Scholar
• Phadke V, Bhardwaj S, Sahoo B, et al. Maternal ingestion of diclofenac leading to renal failure in newborns. Pediatr Nephrol. 2012;27(6):1033–1036. doi: 10.1007/s00467-012-2114-z.
   PubMed Web of Science ®Google Scholar
• Voyer LE, Drut R, Mendez JH. Fetal renal maldevelopment with oligohydramnios following maternal use of piroxicam. Pediatr Nephrol. 1994;8(5):592–594. doi: 10.1007/BF00858136.
   PubMed Web of Science ®Google Scholar
• Savage AH, Anderson BL, Simhan HN. The safety of prolonged indomethacin therapy. Am J Perinatol. 2007;24(4):207–213. doi: 10.1055/s-2007-976546.
   PubMed Web of Science ®Google Scholar
• Grincevičienė Š, Volochovič J, Grincevičius J. Lack of pharmacist–physician communication associated with nimesulide-induced oligohydramnios during pregnancy. Int J Clin Pharm. 2016;38(2):196–198. doi: 10.1007/s11096-016-0267-8.
   PubMed Web of Science ®Google Scholar
• Sandruck JC, Grobman WA, Gerber SE. The effect of short-term indomethacin therapy on amniotic fluid volume. Am J Obstet Gynecol. 2005;192(5):1443–1445. doi: 10.1016/j.ajog.2004.12.036.
   PubMed Web of Science ®Google Scholar
• Sawdy RJ, Groom KM, Bennett PR. Experience of the use of nimesulide, a cyclo-oxygenase-2 selective prostaglandin synthesis inhibitor, in the prevention of preterm labour in 44 high-risk cases. J Obstet Gynaecol. 2004;24(3):226–229. doi: 10.1080/01443610410001660661.
   PubMedGoogle Scholar
• Paternoster DM, Snijders D, Manganelli F, et al. Anhydramnios and maternal thrombocytopenia after prolonged use of nimesulide. Eur J Obstet Gynecol Reprod Biol. 2003;108(1):97–98. doi: 10.1016/s0301-2115(02)00343-3.
   PubMed Web of Science ®Google Scholar
• Locatelli A, Vergani P, Bellini P, et al. Can a cyclo-oxygenase type-2 selective tocolytic agent avoid the fetal side effects of indomethacin? BJOG. 2001;108(3):325–326. doi: 10.1111/j.1471-0528.2001.00071.x.
   PubMedGoogle Scholar
• Kaplan BS, Restaino I, Raval DS, et al. Renal failure in the neonate associated with in utero exposure to non-steroidal anti-inflammatory agents. Pediatr Nephrol. 1994;8(6):700–704. doi: 10.1007/BF00869093.
   PubMedGoogle Scholar
• Carmona F, Martínez-Román S, Mortera C, et al. Efficacy and safety of indomethacin therapy for polyhydramnios. Eur J Obstet Gynecol Reprod Biol. 1993;52(3):175–180. doi: 10.1016/0028-2243(93)90068-n.
   PubMed Web of Science ®Google Scholar
• Bivins HA Jr., Newman RB, Fyfe DA, et al. Randomized trial of oral indomethacin and terbutaline sulfate for the long-term suppression of preterm labor. Am J Obstet Gynecol. 1993;169(4):1065–1070. doi: 10.1016/0002-9378(93)90055-n.
   PubMed Web of Science ®Google Scholar
• Kirshon B, Moise KJ Jr., Mari G, et al. Long-term indomethacin therapy decreases fetal urine output and results in oligohydramnios. Am J Perinatol. 1991;8(2):86–88. doi: 10.1055/s-2007-999349.
   PubMed Web of Science ®Google Scholar
• Hendrick SK, Smith JR, Moore DE, et al. Oligohydramnios associated with prostaglandin synthetase inhibitors in preterm labour. Br J Obstet Gynaecol. 1990;97(4):312–316. doi: 10.1111/j.1471-0528.1990.tb01807.x.
   PubMedGoogle Scholar
• Goldenberg RL, Davis RO, Baker RC. Indomethacin-induced oligohydramnios. Am J Obstet Gynecol. 1989;160(5 Pt 1):1196–1197. doi: 10.1016/0002-9378(89)90188-9.
   PubMed Web of Science ®Google Scholar
• De Wit W, van Mourik I, Wiesenhaan PF. Prolonged maternal indomethacin therapy associated with oligohydramnios. Case reports. Br J Obstet Gynaecol. 1988;95(3):303–305. doi: 10.1111/j.1471-0528.1988.tb06874.x.
   PubMedGoogle Scholar
• Vanhaesebrouck P, Thiery M, Leroy JG, et al. Oligohydramnios, renal insufficiency, and ileal perforation in preterm infants after intrauterine exposure to indomethacin. J Pediatr. 1988;113(4):738–743. doi: 10.1016/s0022-3476(88)80392-5.
   PubMed Web of Science ®Google Scholar
• Rahimi R, Nikfar S, Rezaie A, et al. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. Reprod Toxicol. 2008;25(2):271–275. doi: 10.1016/j.reprotox.2007.11.010.
   PubMed Web of Science ®Google Scholar
• Ofori B, Oraichi D, Blais L, et al. Risk of congenital anomalies in pregnant users of non-steroidal anti-inflammatory drugs: a nested case-control study. Birth Defects Res B Dev Reprod Toxicol. 2006;77(4):268–279. doi: 10.1002/bdrb.20085.
   PubMedGoogle Scholar
• Østensen ME, Skomsvoll JF. Anti-inflammatory pharmacotherapy during pregnancy. Expert Opin Pharmacother. 2004;5(3):571–580. doi: 10.1517/14656566.5.3.571.
   PubMed Web of Science ®Google Scholar
• Li DK, Liu L, Odouli R. Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study. BMJ. 2003;327(7411):368. doi: 10.1136/bmj.327.7411.368.
   PubMedGoogle Scholar
• Auer M, Brezinka C, Eller P, et al. Prenatal diagnosis of intrauterine premature closure of the ductus arteriosus following maternal diclofenac application. Ultrasound Obstet Gynecol. 2004;23(5):513–516. doi: 10.1002/uog.1038.
   PubMed Web of Science ®Google Scholar
• Abou-Ghannam G, Usta IM, Nassar AH. Indomethacin in pregnancy: applications and safety. Am J Perinatol. 2012;29(3):175–186.
   PubMed Web of Science ®Google Scholar
• Boubred F, Vendemmia M, Garcia-Meric P, et al. Effects of maternally administered drugs on the fetal and neonatal kidney. Drug Saf. 2006;29(5):397–419. doi: 10.2165/00002018-200629050-00004.
   PubMed Web of Science ®Google Scholar
• Bloor M, Paech M. Nonsteroidal anti-inflammatory drugs during pregnancy and the initiation of lactation. Anesth Analg. 2013;116(5):1063–1075. doi: 10.1213/ANE.0b013e31828a4b54.
   PubMed Web of Science ®Google Scholar
• Giovanni G, Giovanni P. Do non-steroidal anti-inflammatory drugs and COX-2 selective inhibitors have different renal effects? J Nephrol. 2002;15(5):480–488.
   PubMed Web of Science ®Google Scholar
• Vermillion ST, Scardo JA, Lashus AG, et al. The effect of indomethacin tocolysis on fetal ductus arteriosus constriction with advancing gestational age. Am J Obstet Gynecol. 1997;177(2):256–261. doi: 10.1016/s0002-9378(97)70184-4.
   PubMed Web of Science ®Google Scholar
• vd Heijden AJ, Tibboel D, Fetter WP, et al. Intrauterine exposure to indomethacin. Eur J Pediatr. 1986;145(6):579–579. doi: 10.1007/BF02429073.
   PubMed Web of Science ®Google Scholar
• Fieni S, Gramellini D, Vadora E. Oligohydramnios and fetal renal sonographic appearances related to prostaglandin synthetase inhibitors. A case report. Fetal Diagn Ther. 2004;19(3):224–227. doi: 10.1159/000076702.
   PubMed Web of Science ®Google Scholar
• Dathe K, Hultzsch S, Pritchard LW, et al. Risk estimation of fetal adverse effects after short-term second trimester exposure to non-steroidal anti-inflammatory drugs: a literature review. Eur J Clin Pharmacol. 2019;75(10):1347–1353. doi: 10.1007/s00228-019-02712-2.
   PubMed Web of Science ®Google Scholar